Comparative Pharmacology
Head-to-head clinical analysis: ATROPINE AND DEMEROL versus OXYCET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATROPINE AND DEMEROL versus OXYCET.
ATROPINE AND DEMEROL vs OXYCET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Atropine is an antimuscarinic agent that competitively blocks acetylcholine at muscarinic receptors, reducing secretions and gastrointestinal motility. Meperidine (Demerol) is an opioid agonist that binds to mu-opioid receptors in the CNS, altering pain perception and producing analgesia.
Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, though it can interact with other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Acetaminophen is believed to produce analgesia through central action, possibly mediated through inhibition of cyclooxygenase (COX) and activation of descending serotonergic pathways, though the exact mechanism is not fully understood.
Atropine 0.4 mg and Demerol (meperidine) 50-100 mg intramuscularly as preanesthetic medication 30-60 minutes before procedure.
1 tablet (325 mg acetaminophen and 5 mg oxycodone) orally every 4 to 6 hours as needed for pain; maximum 12 tablets per day.
None Documented
None Documented
Atropine: 2-4 hours (terminal half-life). Demerol: 2.5-4 hours; normeperidine metabolite half-life 15-30 hours (accumulates in renal impairment).
The terminal elimination half-life of oxycodone is approximately 3.5-4 hours for immediate-release formulations. For controlled-release formulations, the half-life is similar due to absorption-limited elimination, but the duration of action is extended due to the formulation. In elderly patients or those with hepatic impairment, half-life may be increased up to 2-fold.
Atropine: approximately 50% excreted unchanged in urine, remainder as metabolites (biliary and renal). Demerol (meperidine): primarily hepatic metabolism; <5% excreted unchanged in urine; metabolites (including normeperidine) excreted renally.
Oxycodone is primarily metabolized in the liver via CYP3A4 to noroxycodone and via CYP2D6 to oxymorphone. Renal excretion accounts for approximately 87% of the administered dose, with 8.1% as unchanged oxycodone, 22.8% as noroxycodone, 9.1% as noroxymorphone, 3.2% as oxymorphone, and others. Fecal excretion is about 10%.
Category C
Category C
Opioid Analgesic Combination
Opioid Analgesic Combination